RU2742607C1 - Получение вирусоподобных частиц вируса гриппа в растениях - Google Patents

Получение вирусоподобных частиц вируса гриппа в растениях Download PDF

Info

Publication number
RU2742607C1
RU2742607C1 RU2019135043A RU2019135043A RU2742607C1 RU 2742607 C1 RU2742607 C1 RU 2742607C1 RU 2019135043 A RU2019135043 A RU 2019135043A RU 2019135043 A RU2019135043 A RU 2019135043A RU 2742607 C1 RU2742607 C1 RU 2742607C1
Authority
RU
Russia
Prior art keywords
influenza
seq
modified
sequence
plant
Prior art date
Application number
RU2019135043A
Other languages
English (en)
Russian (ru)
Inventor
Манон КУТЮР
Марк-Андре Д АУ
Луи-Филипп ВЕЗИНА
Original Assignee
Медикаго Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медикаго Инк. filed Critical Медикаго Инк.
Application granted granted Critical
Publication of RU2742607C1 publication Critical patent/RU2742607C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU2019135043A 2013-03-28 2014-03-28 Получение вирусоподобных частиц вируса гриппа в растениях RU2742607C1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361806227P 2013-03-28 2013-03-28
US61/806,227 2013-03-28
US201461925852P 2014-01-10 2014-01-10
US61/925,852 2014-01-10
US201461971274P 2014-03-27 2014-03-27
US61/971,274 2014-03-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015146097A Division RU2705555C2 (ru) 2013-03-28 2014-03-28 Получение вирусоподобных частиц вируса гриппа в растениях

Publications (1)

Publication Number Publication Date
RU2742607C1 true RU2742607C1 (ru) 2021-02-09

Family

ID=51622327

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2019135043A RU2742607C1 (ru) 2013-03-28 2014-03-28 Получение вирусоподобных частиц вируса гриппа в растениях
RU2015146097A RU2705555C2 (ru) 2013-03-28 2014-03-28 Получение вирусоподобных частиц вируса гриппа в растениях

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015146097A RU2705555C2 (ru) 2013-03-28 2014-03-28 Получение вирусоподобных частиц вируса гриппа в растениях

Country Status (14)

Country Link
US (2) US10358652B2 (enExample)
EP (2) EP2978848B1 (enExample)
JP (2) JP2016516415A (enExample)
KR (1) KR102199018B1 (enExample)
CN (2) CN105247059B (enExample)
AU (1) AU2014245779B2 (enExample)
ES (1) ES2803508T3 (enExample)
IL (2) IL241692B2 (enExample)
MX (1) MX376138B (enExample)
PH (1) PH12015502217A1 (enExample)
RU (2) RU2742607C1 (enExample)
SG (1) SG11201507928QA (enExample)
WO (1) WO2014153674A1 (enExample)
ZA (1) ZA201508327B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
CN103930435A (zh) 2011-09-30 2014-07-16 麦迪卡格公司 增加植物中病毒样颗粒的产率
US12467058B2 (en) 2013-03-28 2025-11-11 Aramis Biotechnologies Inc. Influenza virus-like particle production in plants
WO2014153674A1 (en) * 2013-03-28 2014-10-02 Medicago Inc. Influenza virus-like particle production in plants
DK3092309T3 (da) 2014-01-10 2021-04-12 Medicago Inc Cpmv-forstærkerelementer
US10563213B2 (en) 2014-03-27 2020-02-18 Medicago Inc. Modified CPMV enhancer elements
PT3981437T (pt) 2014-04-23 2025-01-15 Modernatx Inc Vacinas de ácidos nucleicos
FR3054547B1 (fr) 2016-07-29 2020-06-05 Angany Inc. Particules pseudo-virales et leurs utilisations
GB201614485D0 (en) 2016-08-25 2016-10-12 Univ Oxford Innovation Ltd Immunogenic composition
CN106822887A (zh) * 2017-01-26 2017-06-13 中国科学院微生物研究所 一种流感病毒四价亚单位疫苗及其应用
RU2020132255A (ru) 2018-03-14 2022-04-15 Медикаго Инк. Энхансер экспрессии в растениях
CN112639100A (zh) * 2018-06-27 2021-04-09 麦迪卡格公司 流感病毒血凝素突变体
CA3133166A1 (en) * 2019-03-14 2020-09-17 Mitsubishi Tanabe Pharma Corporation Endogenous plant expression enhancer
CN113249399B (zh) * 2021-05-27 2022-08-02 长沙诺合松生物科技合伙企业(有限合伙) pAM基因及其植物表达载体和应用
AU2022425707A1 (en) * 2021-12-31 2024-07-04 Mynvax Private Limited Polypeptide fragments, immunogenic composition against influenza virus, and implementations thereof
WO2025102071A1 (en) * 2023-11-09 2025-05-15 The General Hospital Corporation Hemagglutinin polypeptides and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076778A1 (en) * 2007-11-27 2009-06-25 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
WO2011035422A1 (en) * 2009-09-22 2011-03-31 Medicago Inc. Method of preparing plant-derived vlps

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
WO2000020557A2 (en) 1998-10-07 2000-04-13 Boyce Institute For Plant Research At Cornell University Gemini virus vectors for gene expression in plants
US20020169306A1 (en) * 1999-05-18 2002-11-14 Kaio Kitazato Envelope gene-deficient paramyxovirus vector
CA2406668C (en) 1999-12-06 2015-11-24 Board Of Trustees Of The University Of Illinois High affinity tcr proteins and methods
DE10109354A1 (de) 2001-02-27 2002-09-05 Icon Genetics Ag Rekombinante virale Schaltersysteme
US20030180756A1 (en) * 2002-03-21 2003-09-25 Yang Shi Compositions and methods for suppressing eukaryotic gene expression
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7132291B2 (en) 2003-05-05 2006-11-07 Dow Agro Sciences Llc Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
AU2004235800B2 (en) * 2003-05-05 2010-02-18 Dow Agrosciences Llc Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
ES2381200T3 (es) 2005-04-29 2012-05-24 University Of Cape Town Expresión de proteínas virales en las plantas
CN103865892B (zh) * 2005-10-18 2017-04-12 诺瓦瓦克斯股份有限公司 功能性流感病毒样颗粒(vlp)
WO2007100584A2 (en) 2006-02-16 2007-09-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antiviral agents and vaccines against influenza
EP1991264B1 (en) * 2006-03-07 2015-01-07 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
US7618815B2 (en) 2006-03-08 2009-11-17 University Of Kentucky Research Foundation Viral vectors useful in soybean and methods of use
WO2007135480A1 (en) 2006-05-22 2007-11-29 Plant Bioscience Limited Bipartite system, method and composition for the constitutive and inducible expression of high levels of foreign proteins in plants
AU2007286161B2 (en) 2006-08-09 2013-05-02 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8697088B2 (en) 2007-05-25 2014-04-15 Novavax, Inc. VLPs derived from cells that do not express a viral matrix or core protein
MX2009013665A (es) 2007-06-15 2010-06-02 Medicago Inc Produccion modificada de glicoproteinas en plantas.
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
GB0800272D0 (en) 2008-01-08 2008-02-13 Plant Bioscience Ltd Protein expression systems
SG187500A1 (en) * 2008-01-21 2013-02-28 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
CN105753948A (zh) 2008-07-08 2016-07-13 麦迪卡格公司 可溶性重组流感抗原
CA2730668C (en) 2008-07-18 2020-04-28 Medicago Inc. New influenza virus immunizing epitope
CA2736796A1 (en) 2008-08-27 2010-03-04 Arizona Board Of Regents For And On Behalf Of Arizona State University A dna replicon system for high-level rapid production of vaccines and monoclonal antibody therapeutics in plants
EP3009145A1 (en) * 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
EP2445928B1 (en) * 2009-06-24 2018-03-28 Medicago Inc. Chimeric influenza virus-like particles comprising hemagglutinin
FR2947875B1 (fr) 2009-07-10 2011-07-08 Raymond A & Cie Dispositif de fixation a elements de fixation multiples dont l'un est flottant
WO2011011390A1 (en) 2009-07-20 2011-01-27 Novavax, Inc. Purified recombinant influenza virus ha proteins
US20120185969A1 (en) 2009-09-04 2012-07-19 Syngenta Participations Ag Stacking of translational enhancer elements to increase polypeptide expression in plants
WO2011102900A1 (en) 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
SG189236A1 (en) * 2010-10-04 2013-05-31 Massachusetts Inst Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
CA2815887C (en) 2010-11-04 2013-12-10 Medicago Inc. Plant expression system
TWI526539B (zh) 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
BR112013032033A2 (pt) 2011-06-13 2017-05-30 Medicago Inc produção de partícula simular ao vírus da raiva em plantas
PL220281B1 (pl) * 2011-09-23 2015-09-30 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciała specyficznie rozpoznające białko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA
CN103930435A (zh) * 2011-09-30 2014-07-16 麦迪卡格公司 增加植物中病毒样颗粒的产率
US11390878B2 (en) * 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
JP6390846B2 (ja) 2011-11-11 2018-09-19 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ニコチアナタバカムにおいて生成される血球凝集素を含むインフルエンザウイルス様粒子（ｖｌｐ）
EP2876161B1 (en) * 2012-07-23 2018-12-05 The Institute of Biological Resources Vaccine
WO2014153674A1 (en) * 2013-03-28 2014-10-02 Medicago Inc. Influenza virus-like particle production in plants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076778A1 (en) * 2007-11-27 2009-06-25 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
WO2011035422A1 (en) * 2009-09-22 2011-03-31 Medicago Inc. Method of preparing plant-derived vlps

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ERICH HOFFMANN et al., Eight-plasmid system for rapid generation of influenza virus vaccines, Vaccine 2002, Vol. 20, pp. 3165-3170. *
N. V. Petukhova et al., Virus-like particles - a new strategy for the development of influenza vaccines, Problems of Virology, 2013, vol. 58, pp. 10-14. *
TAISUKE HORIMOTO et al., The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate, Vaccine 2006, Vol. 24, pp. 3669-3676. *
TAISUKE HORIMOTO et al., The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate, Vaccine 2006, Vol.24, pp. 3669-3676. ERICH HOFFMANN et al., Eight-plasmid system for rapid generation of influenza virus vaccines, Vaccine 2002, Vol.20, pp.3165-3170. ПЕТУХОВА Н.В. и др., Вирусоподобные частицы - новая стратегия для создания противогриппозных вакцин, Вопросы вирусологии, 2013, т.58, стр.10-14. *

Also Published As

Publication number Publication date
CN105247059A (zh) 2016-01-13
AU2014245779A1 (en) 2015-10-22
US20160122777A1 (en) 2016-05-05
KR20150134423A (ko) 2015-12-01
EP2978848A4 (en) 2016-11-16
JP7065803B2 (ja) 2022-05-12
HK1220729A1 (en) 2017-05-12
NZ712752A (en) 2021-06-25
IL241692B1 (en) 2023-08-01
BR112015024790A2 (pt) 2017-10-10
CN105247059B (zh) 2021-07-06
MX376138B (es) 2025-03-07
KR102199018B1 (ko) 2021-01-07
IL241692B2 (en) 2023-12-01
AU2014245779B2 (en) 2020-02-06
RU2015146097A (ru) 2017-05-04
US11085049B2 (en) 2021-08-10
EP2978848A1 (en) 2016-02-03
ES2803508T3 (es) 2021-01-27
CN112592389A (zh) 2021-04-02
JP2019141061A (ja) 2019-08-29
ZA201508327B (en) 2022-08-31
PH12015502217B1 (en) 2016-02-01
JP2016516415A (ja) 2016-06-09
RU2705555C2 (ru) 2019-11-07
PH12015502217A1 (en) 2016-02-01
WO2014153674A1 (en) 2014-10-02
CA2907591A1 (en) 2014-10-02
IL241692A (enExample) 2015-11-30
MX2015013700A (es) 2016-02-29
SG11201507928QA (en) 2015-10-29
US20200255849A1 (en) 2020-08-13
US10358652B2 (en) 2019-07-23
EP3626827A1 (en) 2020-03-25
EP2978848B1 (en) 2020-05-06
IL295155A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
US11085049B2 (en) Influenza virus-like particle production in plants
IL263643B (en) Air intake system for engines
RU2682752C2 (ru) Повышение выхода вирусоподобных частиц в растениях
US12467058B2 (en) Influenza virus-like particle production in plants
CA2907591C (en) Influenza virus-like particle production in plants
HK1220729B (en) Influenza virus-like particle production in plants
BR112015024790B1 (pt) Ácido nucleico, método de produção de partícula semelhante a vírus influenza (vlp) em plantas, vlp, seu uso, método de produção de uma proteína ha modificada, ha modificada de influenza e composição
NZ712752B2 (en) Influenza virus-like particle production in plants
HK1200179B (en) Increasing virus-like particle yield in plants